Authors
Aaron T Gerds, Abiola Oladapo, Karisse Roman-Torres, Stephen T Oh
Published in
Future oncology (London, England). Pages 1-9. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
In the PERSIST-2 trial (NCT02055781), pacritinib (PAC) demonstrated significant anemia benefit versus best available therapy (BAT). This analysis aimed to estimate projected differences in transfusion-related cost and time burden with PAC versus BAT from a US payer perspective.
An economic evaluation was conducted using red blood cell (RBC) transfusion-related data of patients treated with PAC or BAT from PERSIST-2 trial. Transfusion status (transfusion independent [TI] or non-TI) at baseline (90 days pre-randomization) and during the study (over any 12-week interval through week 24) was defined using Gale criteria. Mean 30-day RBC transfusion rates were annualized and used as proxy for transfusion-related visits. Annual transfusion-related cost/time burden per patient by transfusion status were estimated.
Annual transfusion-related cost and time burden with PAC were projected to be 19.5% and 25.3% lower than with BAT ($252,057 vs $312,969; 507.9 vs 680.4 hours), with per patient cost and time savings of $60,912 and 172.4 hours, respectively. Patients who were non-TI at baseline had higher projected annual cost ($73,095/patient) and time savings (204.3 hours/patient) for PAC versus BAT.
Reduced transfusion rates with PAC versus BAT were projected to decrease transfusion-related medical costs and time burden in patients with cytopenic MF.
PMID:
43016247
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0